$Ironwood Pharmaceuticals (IRWD.US)$Revenue has fluctuated o...
$Ironwood Pharmaceuticals (IRWD.US)$Revenue has fluctuated over the past 5 years, with an average growth rate of 6.6%. Operating profit increased continuously for 4 years after reversing losses in 2019. The average growth rate in the past 3 years was 28.8%, and the growth rate fell to 7.8% in 2022. Net profit reached 530 million in 2021 due to income tax rebates. The average growth rate in the past 3 years was 100%, and the average growth rate in the past 2 years was 28%.
The income statement shows that interest changed from expenses to income in 2022, eliminating the interest burden.
2023Q1 revenue increased 6.7%, operating profit increased 3.9%, and net profit increased 17.8%.
The balance ratio fell from 159% to 40.7% in the past 5 years, and fell further to 38.8% in 2023Q1.
The balance sheet shows that cash reached 660 million at the end of 2022, and long-term loans of 396 million yuan. This should be the reason why interest burdens disappeared. In 2023Q1, cash reached 740 million, long-term loans reached 397 million, and cash increased further. , There is no inventory, and the growth rate and ratio of accounts receivable is normal.
Net cash flow has far exceeded net investment in the past 3 years, and the ability to generate cash is extremely strong.
Currently, the price-earnings ratio is 10.4, and the price-earnings ratio TTM has dropped to 10. You can choose (⭐️⭐️)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
